SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
企業コードSIGA
会社名SIGA Technologies Inc
上場日Sep 09, 1997
最高経営責任者「CEO」Nguyen (Diem)
従業員数46
証券種類Ordinary Share
決算期末Sep 09
本社所在地31 East 62Nd Street
都市NEW YORK
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号10065
電話番号12126729100
ウェブサイトhttps://www.siga.com/
企業コードSIGA
上場日Sep 09, 1997
最高経営責任者「CEO」Nguyen (Diem)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし